DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...
When Margie Wilson was diagnosed with endometrial cancer in 2016 after she experienced unexplained bleeding, she knew nothing ...
By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
Women should be vigilant about subtle bodily changes that could signal cancer. Persistent bloating, unusual vaginal bleeding, unexplained bruising, lo ...
The Ontario Health Professions Appeal and Review Board asked the Inquiries, Complaints, and Reports Committee of the College of Physicians and Surgeons of Ontario to reconsider its decision to require ...
The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate ® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined ...
1. In this cohort study, patients with early-stage, low-grade endometrial cancer who did not undergo hysterectomy, specifically those from racial and ethnic minorities or age extremes, had ...
ABSTRACT: Endometrial cancer is a common malignant tumor among women in China, with 77,000 new cases and 13,500 deaths reported in 2022. Its incidence continues to rise alongside increased lifespan ...
The conversation often begins with subtle changes that women might initially dismiss as normal variations in their monthly cycle. Perhaps unusual bleeding between periods, or discharge that seems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback